A European Society of Human Genetics (ESHG) presentation highlighted how combining genetic ancestry information with tumor mutation profiling can improve survival prediction in cancer. The study analyzed nearly 1,900 tumor-specific genetic mutations and found that ancestry-linked factors influenced both disease trajectory and overall survival outcomes. The work frames ancestry as a meaningful covariate in predictive modeling, suggesting that survival algorithms may underperform if they treat genetic origin as absent or purely confounding. For clinical decision support and stratification, the implication is increased emphasis on integrating origin-informed biological variation into analytic pipelines.